A Phase I Study of Motexafin Gadolinium (Xcytrin NSC 695238) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood.

Trial Profile

A Phase I Study of Motexafin Gadolinium (Xcytrin NSC 695238) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2013

At a glance

  • Drugs Motexafin gadolinium (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Dec 2010 Planned end date added 1 Mar 2007 as reported by ClinicalTrials.gov.
    • 16 Nov 2010 Status changed from completed to recruiting as reported by ClinicalTrials.gov.
    • 06 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top